Luis Miguel
Antón Aparicio
Pfizer (United States)
Nueva York, Estados UnidosPublicacións en colaboración con investigadores/as de Pfizer (United States) (6)
2018
-
Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies
Expert Opinion on Drug Safety, Vol. 17, Núm. 6, pp. 573-579
2014
-
Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer
Clinical Cancer Research, Vol. 20, Núm. 7, pp. 1925-1934
2012
-
MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients
Neoplasia (United States), Vol. 14, Núm. 12, pp. 1144-1152
2011
-
Expression of notch1 to -4 and their ligands in renal cell carcinoma: A tissue microarray study
Cancer Genomics and Proteomics, Vol. 8, Núm. 2, pp. 93-101
-
Fructose transporter GLUT5 expression in clear renal cell carcinoma
Oncology Reports, Vol. 25, Núm. 2, pp. 315-323
2010
-
Glucose transporter expression and the potential role of fructose in renal cell carcinoma: A correlation with pathological parameters
Molecular Medicine Reports, Vol. 3, Núm. 4, pp. 575-580